Citadel Advisors
STAB

Citadel Advisors’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Citadel Advisors’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-20,368
Closed -$5.27K – 14669
2022
Q1 		$7K Buy
+20,368
New +$21.8K ﹤0.01% 13407
2021
Q2 		– Sell
-36,626
Closed -$192K – 14740
2021
Q1 		$192K Buy
36,626
+25,471
+228% +$139K ﹤0.01% 11753
2020
Q4 		$38K Buy
+11,155
New +$31.8K ﹤0.01% 10664
2020
Q2 		– Sell
-12,009
Closed -$20K – 10739
2020
Q1 		$20K Buy
+12,009
New +$24.5K ﹤0.01% 9306
2019
Q4 		– Sell
-28,435
Closed -$29K – 9984
2019
Q3 		$29K Buy
+28,435
New +$38.3K ﹤0.01% 8860
2018
Q3 		– Sell
-15,389
Closed -$38K – 9869
2018
Q2 		$38K Buy
15,389
+1,888
+14% +$5.25K ﹤0.01% 8496
2018
Q1 		$41K Buy
+13,501
New +$47.6K ﹤0.01% 7983
2017
Q4 		– Sell
-10,032
Closed -$35K – 8593
2017
Q3 		$35K Sell
10,032
-5,686
-36% -$16.1K ﹤0.01% 7260
2017
Q2 		$46K Buy
+15,718
New +$51.4K ﹤0.01% 7116
2016
Q4 		– Sell
-29,899
Closed -$52K – 8038
2016
Q3 		$52K Buy
+29,899
New +$65.7K ﹤0.01% 6843
2014
Q4 		– Sell
-2,386
Closed -$22K – 8813
2014
Q3 		$22K Buy
+2,386
New +$21.9K ﹤0.01% 7367
2014
Q1 		– Sell
-427
Closed -$10K – 8072
2013
Q4 		$10K Sell
427
-158
-27% -$4.3K ﹤0.01% 6710
2013
Q3 		$18K Buy
585
+273
+88% +$9.03K ﹤0.01% 6275
2013
Q2 		$10K Buy
+312
New +$10.7K ﹤0.01% 6242

Other funds holding STAB

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Securities
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors's STAB Position: Q2 2022 in Review

Citadel Advisors sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q2 2022, closing a stake of 20,368 shares — an estimated $5.27K sold.

Citadel Advisors first reported a position in STAB in Q2 2013 and held it in 14 quarters. The position peaked at $192K in Q1 2021. 35 funds tracked by Wall St. Rank hold STAB as of Q2 2022.

  • Citadel Advisors reported no remaining Statera Biopharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Citadel Advisors sold 20,368 Statera Biopharma, Inc. Common Stock shares in Q2 2022, an estimated $5.27K.
  • Citadel Advisors first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2013 and held it in 14 quarters.
  • Citadel Advisors's Statera Biopharma, Inc. Common Stock position peaked at $192K in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.